Tumor Necrosis Factor News and Research

RSS

Inflammatory status upregulated in first-episode schizophrenia

Patients with first-episode schizophrenia exhibit upregulation of key proinflammatory molecules, study findings show.

28 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

The National Psoriasis Foundation awarded Zelma Chiesa Fuxench, M.D., of the University of Pennsylvania, its inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship, recognizing her work as a promising psoriasis and psoriatic arthritis researcher.

9 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Six of the top scientists studying psoriasis-the most common autoimmune disease in the country, affecting 7.5 million Americans-and psoriatic arthritis, an inflammatory joint and tendon disease affecting up to 30 percent of people with psoriasis, received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for these chronic diseases.

5 Jun 2013

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis patients had an overall adherence rate to prescribed oral medications at 80% or greater.

1 Jun 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Prednisone and non-steroidal anti-inflammatory drugs (NSAIDs) can be used for symptom control, but to prevent joint damage, we use disease-modifying anti-rheumatic drugs (DMARDs) including the cornerstone, methotrexate.

13 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

30 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).

22 Apr 2013

Study: Women with RA exposed to anti-tumor necrosis drugs may have increased abortion rates

A new study published in the American College of Rheumatology (ACR) journal, Arthritis Care & Research, reveals that women with rheumatoid arthritis (RA) who were on methotrexate (MTX), a drug commonly used to reduce inflammation caused by RA, had lower rates of induced abortions compared to women with RA who were not exposed to the medication.

16 Apr 2013

Researchers unravel dual role of tumor necrosis factor in TB

Tumor necrosis factor - normally an infection-fighting substance produced by the body- can actually heighten susceptibility to tuberculosis if its levels are too high.

12 Apr 2013

Tumor Necrosis Factor News and Research

Inflammatory status upregulated in first-episode schizophrenia

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

Study: Biologic response modifying drugs can cause acute liver injury

Specific inflammatory pattern found in patients with pneumonia and COPD

Specific inflammatory pattern found in patients with pneumonia and COPD

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Study: Women with RA exposed to anti-tumor necrosis drugs may have increased abortion rates

Researchers unravel dual role of tumor necrosis factor in TB

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News